“Multi Module Community Based Blood Test for Early Lung Cancer Detection”
Professor Caroline Dive CBE, PhD, FBPhS, FMedSci
Interim Director of CRUK Manchester Institute, Director of CRUK MI Cancer Biomarker Centre
Professor of Pharmacology, University of Manchester
Zoom Webinar Details
Webinar URL: https://stanford.zoom.us/s/98087764380
Dial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Webinar ID: 980 8776 4380
Passcode: 089027
ABSTRACT
Caroline Dive1, Elaine Kilgour1, Alastair Kerr1, Dominic Rothwell1, Peter Kuhn2 Max Diehn3 and Phil Crosbie4
1CRUK Manchester Institute Cancer Biomarker Centre, University of Manchester, UK; 2Michelson Centre for Convergent Bioscience, University of Southern California, USA; 3Dept. of Radiation Oncology & Stanford Cancer Institute, Stanford University, USA; 4Faculty of Biology, Medicine and Health, University of Manchester, UK.
Low Dose Computerised Tomography (LDCT) scans, performed in the community has delivered a significant stage shift in lung cancer detection (from incurable stage 4 to curable stage 1) and become a routine NHS service in North Manchester, UK. However, the issue of indeterminate nodules by imaging, false positive scans and challenges associated with multiple repeat LDCT scans remain. An easily repeatable, sensitive and specific early detection blood test incorporating a molecular profile that distinguishes indolent versus aggressive tumour biologies would be transformative alongside LDCT screening.
I will describe the ongoing efforts of our transatlantic team to deliver this ambitious goal of a robust early detection multi-modal blood test combining ctDNA mutation, methylation and copy number analyses with circulating tumour cell candidates. We are collecting thousands of blood samples from ‘high risk’ individuals in Manchester undergoing LDCT scans in their community supermarket car parks. These samples provide an ideal opportunity to develop and test liquid biopsies (circulating nucleic acids, proteins and cells) incorporating samples from individuals with true and false positive LDCT scans as well as true negatives samples from individuals with respiratory conditions that often predispose to or accompany an early lung cancer diagnosis such as COPD and emphysema.
ABOUT
After completing her PhD studies in Cambridge, Caroline moved to Aston University’s School of Pharmaceutical Sciences in Birmingham where she started her own group studying mechanisms of drug induced tumour cell death. She then moved as a Cancer Research Campaign fellow to the Faculty of Life Sciences at The University of Manchester to continue this research. Caroline was awarded a Lister Institute of Preventative Medicine Research Fellowship before moving to the CRUK Manchester Institute in 2003. Caroline now directs the Cancer Research UK Manchester Institute Cancer Biomarker Centre.
Caroline was awarded the Pasteur-Weizmann/Servier International Prize in 2012 for her Biomarker Research and the AstraZeneca Prize for Women in Pharmacology in 2016. She is an elected Fellow of the Academy of Medical Sciences (2015), Fellow of the British Pharmacological Society (2012) and Fellow of the European Academy of Cancer Sciences (2011). In 2017, Caroline was awarded Commander of the Order of the British Empire (CBE) for her services to cancer research. Most recently, Caroline was presented with the 2019 Heine H. Hansen Lectureship Award by the International Association for the Study of Lung Cancer (IASLC) and is the EACR President 2020 – 2022.
Hosted by: Utkan Demirci, Ph.D.
Sponsored by: The Canary Center & the Department of Radiology
Stanford University – School of Medicine